Orphanet: Eenvoudig zoeken

Zoek een klinische studie of trial

Andere zoekoptie(s)

231 Resultaat/Resultaten

Nationale klinische studie(s)

Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy Institution: Information not provided - US

STEP: Sorafenib Long Term Extension Program - BE Cliniques universitaires Saint-Luc - UCLouvain Pneumologie_Oncologie thoracique

PHITT: Paediatric Hepatic International Tumour Trial - DE Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital Zentrum für Pädiatrische Hämatologie und Onkologie

A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer -DE- Institution: Information not provided - DE

A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma - IT Institution: Information not provided - IT

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO U.O. di Oncoematologia

An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors (Phase 2) - AT Institution: Information not provided - AT

PHITT: Paediatric Hepatic International Tumour Trial (Phase 3) - AT Institution: Information not provided - AT

PHITT: Paediatric Hepatic International Tumour Trial -ES Institution: Information not provided - ES

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Institution: Information not provided - US

SIOPEL 4: Intensified Pre-Operative Chemotherapy And Radical Surgery For High Risk Hepatoblastoma (Phase II/III) Royal Bournemouth Hospital Department of Haematology

SIOPEL 6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate in reducing ototoxicity in patients receiving cisplatin chemotherapy for standard risk hepatoblastoma (Phase III) - IE Royal Bournemouth Hospital Department of Haematology

A Pilot Study of BMS-936558 With Stereotactic Ablative Radiation Therapy After Induction Chemotherapy in Cholangiocarcinoma - BE Institut Jules Bordet Instituut Oncologie digestive

PRECISION 2: Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination (HR) Genes, a Belgian Precision phase II basket study Universitair Ziekenhuis Brussel Oncologisch centrum

pro-duct: Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer (Phase II) Charité - Universitätsmedizin Berlin

ADJUBIL: A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer Krankenhaus Nordwest GmbH Institut für Klinische Krebsforschung IKF GmbH

NEOBIL: Neoadjuvant Bintrafusp alfa in patients with resectable biliary tract cancer Universitätsklinikum Frankfurt Medizinische Klinik 1 - Bereich Gastroenterologie und Hepatologie

Phase II Study of Immunotherapy With Durvalumab (MEDI4736) or Durvalumab and Tremelimumab, Both Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) Medizinische Hochschule Hannover Klinik für Gastroenterologie, Hepatologie und Endokrinologie

The NACHO trial : Nab-Paclitaxel (Abraxane®) and Gemcitabine as first line therapy in patients with cholangiocarcinoma ineligible for cisplatin-based chemotherapy - a pilot study (GEMNABCCC-001) Universitätsklinikum Essen

AMEBICA : Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours CHU de Saint-Étienne - Hôpital Bellevue Service de Gastro-entérologie et Hépatologie - Cancérologie digestive

ACTICCA-1: Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (Phase 3) - AT Institution: Information not provided - AT

Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer - AT Institution: Information not provided - AT

Open-label First Line, Single-arm Phase II Study of CisGem Combined With Pembrolizumab in Patients With Advanced or Metastatic Biliary Tract Cancer - AT Institution: Information not provided - AT

FORTITUDE-301: A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression - AT Institution: Information not provided - AT

Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study -ES Hospital Universitari Vall d'Hebron Servicio de Cirugía Hepatobiliopancreática y Trasplantes

KEYNOTE-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors -ES Institution: Information not provided - ES

The PROOF Trial: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocation - ES Institution: Information not provided - ES

FOENIX-CCA3: A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements - ES Institution: Information not provided - ES

HERIZON-BTC-01: A Phase 2b, open-label, single-arm study of ZW25 monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers -ES Institution: Information not provided - ES

KEYNOTE-966: A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma - ES Institution: Information not provided - ES

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Institution: Information not provided - US

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) Institution: Information not provided - US

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Institution: Information not provided - US

TAS-102 in Treating Advanced Biliary Tract Cancers Institution: Information not provided - US

A Phase 1/2a Study in 3 Parts (Phase 1a and Phase 1b - Dose Escalations and Phase 2a Expansion Cohorts) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients with Liver Cancer Manifestations-GB Beatson West of Scotland Cancer Centre

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - GB Institution: Information not provided - CH

KEYNOTE-240: A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma -DE- Institution: Information not provided - DE

The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage Hepatocellular carcinoma -DE Universitätsmedizin Mainz I. Medizinische Klinik und Poliklinik

A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib Plus Erlotinib vs. Sorafenib Plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC) Institution: Information not provided - FR

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (Phase III) - FR Institution: Information not provided - FR

HIPANIV: A Phase I Study Evaluating Safety and Efficacy of Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma -FR Institution: Information not provided - FR

Neoadjuvant Atezolizumab and Adjuvant Atezolizumab + Bevacizumab in Combination With Percutaneous Radiofrequency Ablation of Small HCC: a Multicenter Randomized Phase II Trial ICM - Institut régional du Cancer de Montpellier Service d'oncologie médicale - Médecine B3

A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Hepatocellular Carcinoma Institution: Information not provided - JP

Nivolumab and Ipilimumab or Nivolumab or Placebo Plus TACE in Intermediate-stage Liver Cancer (CA20974W) Institution: Information not provided - JP

Randomized phase III trial of Sorafenib versus Lenvatinib as a second-line treatment after immune check point inhibitor for advanced hepatocellular carcinoma (JON2102-H (SUCCEED)) Kanagawa Cancer Center

CheckMate 459: A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma - AT Allgemeines Krankenhaus der Stadt Wien Klinische Abteilung für Gastroenterologie und Hepatologie

The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage Hepatocellular carcinoma -ES Institution: Information not provided - ES

A Phase I Study of Single Agent SF1126, a Dual PI3 Kinase and Bromodomain Inhibitor, in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A-B7 Cirrhosis Institution: Information not provided - US

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Institution: Information not provided - US

EMERALD-3: A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma - BE Institution: Information not provided - BE

BioPearl Microspheres Loaded With Doxorubicin to Treat Patients With Unresectable HCC: Prospective, Single Arm, Multi-centre Post-market Follow-up Study Cliniques Universitaires de Bruxelles - Hôpital Erasme Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive

TRACE Trial: Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of HCC: A Multicenter Randomized Controlled Trial- BE Ghent University Hospital - UZ Gent Radiologie

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma - CA Institution: Information not provided - CA

HIMALAYA: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma - CA Institution: Information not provided - CA

CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation-CA Institution: Information not provided - CA

EMERALD-3: A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma -CA Institution: Information not provided - CA

An Open-Label Study of Regorafenib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC) after PD-1/PD-L1 Immune Checkpoint Inhibitors -DE Universitätsklinikum Tübingen

CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation -DE- Geschäftsstelle CCC München CCC München - Comprehensive Cancer Center

CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation -DE- Zentrum Innere Medizin (ZIM) Medizinische Klinik und Poliklinik II

A phase I/II, multicenter, open-label study of oral FGF401 in adult patients with hepatocellular carcinoma or solid malignancies characterized by positive FGFR4 and KLB expression -DE- Institution: Information not provided - DE

HIMALAYA: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma -DE- Institution: Information not provided - DE

ARTISTRY-2: A Phase 1/2 study of ALKS 4230 administered subcutaneously as monotherapy and in combination with Pembrolizumab in subjects with advanced solid tumors - DE Institution: Information not provided - DE

EMERALD-3: A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma -DE Institution: Information not provided - DE

c-Met Second-line HCC: A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and Pharmacokinetic of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment - DE Merck KGaA

IMMUNIB - An Open-label, Single-arm Phase II Study of Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma Krankenhaus Nordwest GmbH Institut für Klinische Krebsforschung IKF GmbH

A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma -DE- Krankenhaus Nordwest GmbH Institut für Klinische Krebsforschung IKF GmbH

SOLARIS : A phase-II open-label study of pembrolizumab and lenvatinib in patients with advanced stage hepatocellular carcinoma who are refractory to atezolizumab and bevacizumab/ IO-based therapy Krankenhaus Nordwest GmbH Institut für Klinische Krebsforschung IKF GmbH

IMMUWIN: A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design Medizinische Hochschule Hannover Klinik für Gastroenterologie, Hepatologie und Endokrinologie

A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma -DE- Medizinische Hochschule Hannover Medizinische Hochschule Hannover (MHH)

A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma -DE- Universitätstumorzentrum (UTZ) Centrum für Integrierte Onkologie Düsseldorf

A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma -DE- Universitätsklinikum Köln

A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma -DE- Universitätsmedizin Mainz Universitäres Centrum für Tumorerkrankungen (UCT) Mainz

CaPture: Cabozantinib treatment in a phase II study for patients with hepatocellular carcinoma (HCC) refractory to PD-1 inhibitors Universitätsklinikum Carl Gustav Carus an der TU Dresden Medizinische Klinik und Poliklinik I

CaPture: Cabozantinib treatment in a phase II study for patients with hepatocellular carcinoma (HCC) refractory to PD-1 inhibitors Universitätsklinikum Leipzig AöR Klinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie und Infektiologie

A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma -DE- Universitätsklinikum Leipzig AöR UCCL - Universitäres Krebszentrum Leipzig

A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study) Institution: Information not provided - FR

Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Institution: Information not provided - US

STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain

Pneumologie_Oncologie thoracique

PHITT: Paediatric Hepatic International Tumour Trial - DE
Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital

Zentrum für Pädiatrische Hämatologie und Onkologie

A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer -DE-
Institution: Information not provided - DE

A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma - IT
Institution: Information not provided - IT

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO

U.O. di Oncoematologia

An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors (Phase 2) - AT
Institution: Information not provided - AT

PHITT: Paediatric Hepatic International Tumour Trial (Phase 3) - AT
Institution: Information not provided - AT

PHITT: Paediatric Hepatic International Tumour Trial -ES
Institution: Information not provided - ES

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Institution: Information not provided - US

SIOPEL 4: Intensified Pre-Operative Chemotherapy And Radical Surgery For High Risk Hepatoblastoma (Phase II/III)
Royal Bournemouth Hospital

Department of Haematology

SIOPEL 6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate in reducing ototoxicity in patients receiving cisplatin chemotherapy for standard risk hepatoblastoma (Phase III) - IE
Royal Bournemouth Hospital

Department of Haematology

A Pilot Study of BMS-936558 With Stereotactic Ablative Radiation Therapy After Induction Chemotherapy in Cholangiocarcinoma - BE
Institut Jules Bordet Instituut

Oncologie digestive

PRECISION 2: Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination (HR) Genes, a Belgian Precision phase II basket study
Universitair Ziekenhuis Brussel

Oncologisch centrum

pro-duct: Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer (Phase II)
Charité - Universitätsmedizin Berlin

ADJUBIL: A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer
Krankenhaus Nordwest GmbH

Institut für Klinische Krebsforschung IKF GmbH

NEOBIL: Neoadjuvant Bintrafusp alfa in patients with resectable biliary tract cancer
Universitätsklinikum Frankfurt

Medizinische Klinik 1 - Bereich Gastroenterologie und Hepatologie

Phase II Study of Immunotherapy With Durvalumab (MEDI4736) or Durvalumab and Tremelimumab, Both Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Medizinische Hochschule Hannover

Klinik für Gastroenterologie, Hepatologie und Endokrinologie

The NACHO trial : Nab-Paclitaxel (Abraxane®) and Gemcitabine as first line therapy in patients with cholangiocarcinoma ineligible for cisplatin-based chemotherapy - a pilot study (GEMNABCCC-001)
Universitätsklinikum Essen

AMEBICA : Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours
CHU de Saint-Étienne - Hôpital Bellevue

Service de Gastro-entérologie et Hépatologie - Cancérologie digestive

ACTICCA-1: Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (Phase 3) - AT
Institution: Information not provided - AT

Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer - AT
Institution: Information not provided - AT

Open-label First Line, Single-arm Phase II Study of CisGem Combined With Pembrolizumab in Patients With Advanced or Metastatic Biliary Tract Cancer - AT
Institution: Information not provided - AT

FORTITUDE-301: A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression - AT
Institution: Information not provided - AT

Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study -ES
Hospital Universitari Vall d'Hebron

Servicio de Cirugía Hepatobiliopancreática y Trasplantes

KEYNOTE-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors -ES
Institution: Information not provided - ES

The PROOF Trial: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocation - ES
Institution: Information not provided - ES

FOENIX-CCA3: A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements - ES
Institution: Information not provided - ES

HERIZON-BTC-01: A Phase 2b, open-label, single-arm study of ZW25 monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers -ES
Institution: Information not provided - ES

KEYNOTE-966: A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma - ES
Institution: Information not provided - ES

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Institution: Information not provided - US

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Institution: Information not provided - US

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
Institution: Information not provided - US

TAS-102 in Treating Advanced Biliary Tract Cancers
Institution: Information not provided - US

A Phase 1/2a Study in 3 Parts (Phase 1a and Phase 1b - Dose Escalations and Phase 2a Expansion Cohorts) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients with Liver Cancer Manifestations-GB
Beatson West of Scotland Cancer Centre

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - GB
Institution: Information not provided - CH

KEYNOTE-240: A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma -DE-
Institution: Information not provided - DE

The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage Hepatocellular carcinoma -DE
Universitätsmedizin Mainz

I. Medizinische Klinik und Poliklinik

A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib Plus Erlotinib vs. Sorafenib Plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)
Institution: Information not provided - FR

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (Phase III) - FR
Institution: Information not provided - FR

HIPANIV: A Phase I Study Evaluating Safety and Efficacy of Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma -FR
Institution: Information not provided - FR

Neoadjuvant Atezolizumab and Adjuvant Atezolizumab + Bevacizumab in Combination With Percutaneous Radiofrequency Ablation of Small HCC: a Multicenter Randomized Phase II Trial
ICM - Institut régional du Cancer de Montpellier

Service d'oncologie médicale - Médecine B3

A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Hepatocellular Carcinoma
Institution: Information not provided - JP

Nivolumab and Ipilimumab or Nivolumab or Placebo Plus TACE in Intermediate-stage Liver Cancer (CA20974W)
Institution: Information not provided - JP

Randomized phase III trial of Sorafenib versus Lenvatinib as a second-line treatment after immune check point inhibitor for advanced hepatocellular carcinoma (JON2102-H (SUCCEED))
Kanagawa Cancer Center

CheckMate 459: A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma - AT
Allgemeines Krankenhaus der Stadt Wien

Klinische Abteilung für Gastroenterologie und Hepatologie

The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage Hepatocellular carcinoma -ES
Institution: Information not provided - ES

A Phase I Study of Single Agent SF1126, a Dual PI3 Kinase and Bromodomain Inhibitor, in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A-B7 Cirrhosis
Institution: Information not provided - US

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Institution: Information not provided - US

EMERALD-3: A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma - BE
Institution: Information not provided - BE

BioPearl Microspheres Loaded With Doxorubicin to Treat Patients With Unresectable HCC: Prospective, Single Arm, Multi-centre Post-market Follow-up Study
Cliniques Universitaires de Bruxelles - Hôpital Erasme

Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive

TRACE Trial: Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of HCC: A Multicenter Randomized Controlled Trial- BE
Ghent University Hospital - UZ Gent

Radiologie

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma - CA
Institution: Information not provided - CA

HIMALAYA: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma - CA
Institution: Information not provided - CA

CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation-CA
Institution: Information not provided - CA

EMERALD-3: A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma -CA
Institution: Information not provided - CA

An Open-Label Study of Regorafenib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC) after PD-1/PD-L1 Immune Checkpoint Inhibitors -DE
Universitätsklinikum Tübingen

CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation -DE-
Geschäftsstelle CCC München

CCC München - Comprehensive Cancer Center

CheckMate 9DX: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation -DE-
Zentrum Innere Medizin (ZIM)

Medizinische Klinik und Poliklinik II

A phase I/II, multicenter, open-label study of oral FGF401 in adult patients with hepatocellular carcinoma or solid malignancies characterized by positive FGFR4 and KLB expression -DE-
Institution: Information not provided - DE

HIMALAYA: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma -DE-
Institution: Information not provided - DE

ARTISTRY-2: A Phase 1/2 study of ALKS 4230 administered subcutaneously as monotherapy and in combination with Pembrolizumab in subjects with advanced solid tumors - DE
Institution: Information not provided - DE

EMERALD-3: A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma -DE
Institution: Information not provided - DE

c-Met Second-line HCC: A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and Pharmacokinetic of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment - DE
Merck KGaA

IMMUNIB - An Open-label, Single-arm Phase II Study of Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma
Krankenhaus Nordwest GmbH

Institut für Klinische Krebsforschung IKF GmbH

A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma -DE-
Krankenhaus Nordwest GmbH

Institut für Klinische Krebsforschung IKF GmbH

SOLARIS : A phase-II open-label study of pembrolizumab and lenvatinib in patients with advanced stage hepatocellular carcinoma who are refractory to atezolizumab and bevacizumab/ IO-based therapy
Krankenhaus Nordwest GmbH

Institut für Klinische Krebsforschung IKF GmbH

IMMUWIN: A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design
Medizinische Hochschule Hannover

Klinik für Gastroenterologie, Hepatologie und Endokrinologie

A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma -DE-
Medizinische Hochschule Hannover

Medizinische Hochschule Hannover (MHH)

A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma -DE-
Universitätstumorzentrum (UTZ)

Centrum für Integrierte Onkologie Düsseldorf

A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma -DE-
Universitätsklinikum Köln

A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma -DE-
Universitätsmedizin Mainz

Universitäres Centrum für Tumorerkrankungen (UCT) Mainz

CaPture: Cabozantinib treatment in a phase II study for patients with hepatocellular carcinoma (HCC) refractory to PD-1 inhibitors
Universitätsklinikum Carl Gustav Carus an der TU Dresden

Medizinische Klinik und Poliklinik I

CaPture: Cabozantinib treatment in a phase II study for patients with hepatocellular carcinoma (HCC) refractory to PD-1 inhibitors
Universitätsklinikum Leipzig AöR

Klinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie und Infektiologie

A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma -DE-
Universitätsklinikum Leipzig AöR

UCCL - Universitäres Krebszentrum Leipzig

A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
Institution: Information not provided - FR

RESORCE: A randomized, double blind, placebo-controlled, multicenter phase III study of Regorafenib in patients with Hepatocellular Carcinoma after Sorafenib - FR
Institution: Information not provided - FR

Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis, Phase IIa Clinical Study
Institution: Information not provided - FR

Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma - FR
Institution: Information not provided - FR

TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE for patients with intermediate stage HCC - FR
Institution: Information not provided - FR